Free shipping on all orders over $ 500

Motesanib Diphosphate

Cat. No. M1920

All AbMole products are for research use only, cannot be used for human consumption.

Motesanib Diphosphate Structure
Synonym:

AMG 706

Size Price Availability Quantity
10mg USD 180 In stock
50mg USD 550 In stock
100mg USD 950 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Motesanib diphosphate (AMG 706) is a novel oral inhibitor of VEGF receptors, platelet-derived growth-factor receptor, and KIT. It is used as the phosphate salt motesanib diphosphate. Motesanib Diphosphate significantly inhibits VEGF-induced cellular proliferation of HUVECs with an IC50 of 10 nM, while displaying little effect at bFGF-induced proliferation with an IC50 of >3,000 nM. Motesanib Diphosphate (AMG 706) induces a dose-dependent tumor regression of established A431 xenografts by selectively targeting neovascularization in tumor cells. Motesanib diphosphate (AMG 706) can induce partial responses in patients with advanced or metastatic differentiated thyroid cancer that is progressive.

Chemical Information
Molecular Weight 569.44
Formula C22H23N5O.2H3PO4
CAS Number 857876-30-3
Solubility (25°C) DMSO 100 mg/mL
Water 100 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Li C, et al. Drug Metab Dispos. In vitro metabolism of the novel, highly selective oral angiogenesis inhibitor motesanib diphosphate in preclinical species and in humans.

[2] Sherman SI, et al. N Engl J Med. Motesanib diphosphate in progressive differentiated thyroid cancer.

Related VEGFR/PDGFR Products
ABT-869

ABT-869 (Linifanib) is an ATP-competitive, multi-targeted RTK inhibitor that is completely effective against all members of VEGFR and PDGFR.

Tivozanib (AV-951)

Tivozanib (AV-951) is a potent VEGFR-1, 2 and 3, c-Kit and PDGFR inhibitor with IC50 of 0.21, 0.16, 0.24, 1.63 and 1.72 nM respectively.

Axitinib

Axitinib (AG013736) inhibits multiple targets including VEGFR, PDGFR and cKit.

Regorafenib

Regorafenib (BAY 73-4506) is a novel oral multikinase inhibitor of c-KIT, VEGFR2, B-Raf with IC50s of 17, 40 and 69 nM respectively.

Nintedanib

Nintedanib (BIBF1120) is a novel, potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

  Catalog
Abmole Inhibitor Catalog




Keywords: Motesanib Diphosphate, AMG 706 supplier, VEGFR/PDGFR, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.